Vicore Pharma Holding AB
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Vicore Pharma Holding AB - overview
Established
2000
Location
Stockholm, -, Sweden
Primary Industry
Pharmaceuticals
About
Vicore Pharma Holding AB, based in Sweden, focuses on developing innovative therapies targeting diseases related to the angiotensin II type 2 receptor, aiming to improve treatment outcomes for patients with respiratory conditions. Founded in 2000 in Stockholm, Sweden, Vicore Pharma Holding AB specializes in developing therapies for respiratory diseases. The company has undergone strategic pivots to enhance its focus on innovative drug development. It has successfully raised SEK 102.
000 mn in its latest funding round, LP Direct, with investors including Sanofi, bringing the total amount raised to SEK 102. 000 mn. The company has executed four deals to date and is not structured as a subsidiary of any parent company, nor does it have any disclosed subsidiaries. The current leadership includes CEO Ahmed Mousa and Per Jansson.
Vicore Pharma specializes in innovative therapies targeting diseases where the angiotensin II type 2 (AT2) receptor plays a critical role. Their core product, buloxibutid (C21), is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist currently in phase 2a clinical development for idiopathic pulmonary fibrosis (IPF). Buloxibutid is designed to address the underlying fibrosis in IPF by stimulating the protective aspects of the renin-angiotensin system, thereby promoting alveolar repair and reducing fibrosis formation. Additionally, the company has developed Almee™, a digital therapeutic based on cognitive behavioral therapy aimed at alleviating the psychological impact of living with pulmonary fibrosis; this product has received Breakthrough Device Designation from the FDA.
Vicore Pharma aims to serve patients and families affected by respiratory diseases while expanding its therapeutic portfolio across various international markets. In 2022, Vicore Pharma reported revenues of SEK 0, with an EBITDA of SEK -28,479,520. 4. The revenue generation model is focused on the development and commercialization of its pharmaceutical products and digital therapies.
The company engages in partnerships and collaborations with healthcare organizations and research institutions to facilitate clinical trials and advance its product pipeline. Transactions typically involve direct-to-consumer offerings and B2B arrangements with healthcare providers and insurers for its therapies, particularly buloxibutid and Almee™. Looking ahead, Vicore Pharma plans to expand its product offerings and market reach, actively pursuing new therapeutic developments. The recent funding of SEK 102.
000 mn will support ongoing clinical trials and may facilitate the launch of upcoming products. The company is targeting new geographic markets to increase its presence, although specific regions have not been disclosed. All VC investors have exited their stake in Vicore Pharma Holding AB, indicating a shift in its investment landscape and potential for new strategic directions.
Current Investors
Sanofi
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.vicorepharma.com
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
Vicore Pharma Holding AB - timeline of key events
Vicore Pharma Holding AB - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 2,352,000 | 2,594,000 | 2,585,000 | 851,000 | 840,000 | 852,000 | 932,000 | 508,000 | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | 10.3% | (0.3%) | (67.1%) | (1.3%) | 1.4% | 9.4% | (45.5%) | (100.0%) | - | - | - | - | - |
| EBITDA (USD) | (2,824,000) | (3,112,000) | (2,956,000) | (5,304,000) | (4,537,000) | (6,643,000) | (12,786,000) | (41,579,000) | (92,676,000) | (146,001,000) | (291,220,000) | - | - | - |
| Operating Income (USD) | (2,841,000) | (3,150,000) | (2,996,000) | (5,340,000) | (4,543,000) | (6,649,000) | (12,793,000) | (41,586,000) | (94,014,000) | (149,538,000) | (294,818,000) | - | - | - |
| Operating Margin | (120.8%) | (121.4%) | (115.9%) | (627.5%) | (540.8%) | (780.4%) | (1372.6%) | (8186.2%) | - | - | - | - | - | - |
| % EBITDA Margin | (120.1%) | (120.0%) | (114.4%) | (623.3%) | (540.1%) | (779.7%) | (1371.9%) | (8184.8%) | - | - | - | - | - | - |
| NET Income (USD) | (179,000) | (3,158,000) | (1,603,000) | 13,687,000 | (4,570,000) | (6,652,000) | (12,855,000) | (21,681,000) | (93,084,000) | (146,862,000) | (296,481,000) | - | - | - |
| % Net Margin | (7.6%) | (121.7%) | (62.0%) | 1608.3% | (544.0%) | (780.8%) | (1379.3%) | (4267.9%) | - | - | - | - | - | - |
Vicore Pharma Holding AB - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LP Direct, PIPE | Completed | Vicore Pharma Holding AB | - | ||||||||
| Unspecified Round | Completed | Vicore Pharma Holding AB | - | ||||||||
| Unspecified Round | Completed | Vicore Pharma Holding AB | - | ||||||||
| Unspecified Exit | Completed | Vicore Pharma Holding AB | - |
Displaying 1 - 4 of 4
Vicore Pharma Holding AB - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.